Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Chlorthalidone promotes mineral retention in patients with idiopathic hypercalciuria.

Coe FL, Parks JH, Bushinsky DA, Langman CB, Favus MJ.

Kidney Int. 1988 Jun;33(6):1140-6.

2.

Urinary saturation measurements in calcium nephrolithiasis.

Weber DV, Coe FL, Parks JH, Dunn MS, Tembe V.

Ann Intern Med. 1979 Feb;90(2):180-4.

PMID:
443649
3.

Trichlormethiazide and oral phosphate therapy in patients with absorptive hypercalciuria.

Insogna KL, Ellison AS, Burtis WJ, Sartori L, Lang RL, Broadus AE.

J Urol. 1989 Feb;141(2):269-74.

PMID:
2913343
4.

Responsiveness of hypercalciuria to thiazide in Dent's disease.

Raja KA, Schurman S, D'mello RG, Blowey D, Goodyer P, Van Why S, Ploutz-Snyder RJ, Asplin J, Scheinman SJ.

J Am Soc Nephrol. 2002 Dec;13(12):2938-44.

5.

Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not.

Ettinger B, Citron JT, Livermore B, Dolman LI.

J Urol. 1988 Apr;139(4):679-84.

PMID:
3280829
6.
7.

Role of proximal tubule in the hypocalciuric response to thiazide of patients with idiopathic hypercalciuria.

Bergsland KJ, Worcester EM, Coe FL.

Am J Physiol Renal Physiol. 2013 Aug 15;305(4):F592-9. doi: 10.1152/ajprenal.00116.2013. Epub 2013 May 29.

9.

[Effect of verapamil on urinary calcium and oxalate excretion in renal stone formers].

Iguchi M, Ikegami M, Kiwamoto H, Umekawa T, Ishikawa Y, Kohri K, Kurita T.

Hinyokika Kiyo. 1993 May;39(5):425-31. Japanese.

10.

Hyperoxaluria or hypercalciuria in nephrolithiasis: the importance of renal tubular functions.

Lindsjö M, Fellström B, Danielson BG, Kasidas GP, Rose GA, Ljunghall S.

Eur J Clin Invest. 1990 Oct;20(5):546-54.

PMID:
2124987
11.

The pathogenesis of idiopathic hypercalciuria: evidence for parathyroid hyperfunction.

Evans RA, Hills E, Wong SY, Wyndham LE, Eade Y, Dunstan CR.

Q J Med. 1984 Winter;53(209):41-53.

PMID:
6324269
12.

[Diuretic treatment of recurrent nephrolithiasis caused by idiopathic hypercalciuria].

Birkenhäger JC, Lockefeer J, Bakker NJ.

Ned Tijdschr Geneeskd. 1972 Aug 12;116(33):1485-6. Dutch. No abstract available.

PMID:
5069838
13.

Why oral calcium supplements may reduce renal stone disease: report of a clinical pilot study.

Williams CP, Child DF, Hudson PR, Davies GK, Davies MG, John R, Anandaram PS, De Bolla AR.

J Clin Pathol. 2001 Jan;54(1):54-62.

14.

Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study.

Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A.

J Urol. 1996 Mar;155(3):839-43.

PMID:
8583588
15.

[Hydrochlorothiazide and chlorthalidone in the treatment of patients with calcium-phosphate disorders].

Sawicki A, Soszyński P.

Pol Tyg Lek. 1984 Jul 16-23;39(29-30):993-7. Polish. No abstract available.

PMID:
6504725
16.

[Optimal dosage of chlorthalidone in the prevention of the recurrence of nephrolithiasis is 25 mg per day].

Jaeger P, Portmann L, Jacquet AF, Bugnon JM, Burckhardt P.

Schweiz Med Wochenschr. 1986 Mar 8;116(10):305-8. French.

PMID:
3961448
17.

Effects of short and long-term indapamide treatments on urinary calcium excretion in patients with calcium oxalate dihydrate urinary stone disease: a pilot study.

Alonso D, Pieras E, Pizá P, Grases F, Prieto RM.

Scand J Urol Nephrol. 2012 Apr;46(2):97-101. doi: 10.3109/00365599.2011.644862. Epub 2012 Jan 18.

PMID:
22251010
18.

Chlorthalidone improves vertebral bone quality in genetic hypercalciuric stone-forming rats.

Bushinsky DA, Willett T, Asplin JR, Culbertson C, Che SP, Grynpas M.

J Bone Miner Res. 2011 Aug;26(8):1904-12. doi: 10.1002/jbmr.374.

19.

Hydrochlorothiazide compared to chlorthalidone in reduction of urinary calcium in patients with kidney stones.

Wolfgram DF, Gundu V, Astor BC, Jhagroo RA.

Urolithiasis. 2013 Aug;41(4):315-22. doi: 10.1007/s00240-013-0568-5. Epub 2013 May 10.

PMID:
23660825
20.

Association between vitamin D receptor gene polymorphisms and fasting idiopathic hypercalciuria in recurrent stone-forming patients.

Rendina D, Mossetti G, Viceconti R, Sorrentino M, Castaldo R, Manno G, Guadagno V, Strazzullo P, Nunziata V.

Urology. 2004 Oct;64(4):833-8.

PMID:
15491743

Supplemental Content

Support Center